In May, the US Division of Health and Human Services (HHS) introduced a brand new rule challenging that direct-to-consumer TV commercial for specific pharmaceuticals and biologics state the list value of the drugs being marketed.
The rule was introduced by HHS secretary Alex Azar as a part of his efforts – along with President Donald Trump – to reduce drug prices and to increase transparency about costs.
On Friday, three prime USA-located pharma firms and the Association of National Advertisers, filed a lawsuit in the US District Court for the District of Columbia, seeking to forestall the rule from taking effect on July 9.
The three corporations are Amgen (Nasdaq: AMGN), Merck & Co (NYSE: MRK) and Eli Lilly (NYSE: LLY).
Amgen has released a statement explaining its role, stating: “Amgen is of the same opinion as to the management that patients need clear and relevant data to understand what they are be expecting to pay for their medications. We have now already taken proactive measures in our direct-to-consumer (DTC) TV promoting and similar product websites to make stronger pricing transparency.
The statement adds: “What Amgen doesn’t believe is a government-prescribed way as required in the new DTC rule. Not only does the guideline lift critical freedom of speech concerns, but it also mandates a way that fails to account for variations among insurance coverage, remedies, and sufferers themselves, by requiring disclosure of listing price.
This complaint originates from the fact that the list price that may be marketed isn’t actually what sufferers would most likely pay, since there are often rebates that move to pharmacy benefit managers, and insurance coverage contributions too can result in diversifications.
In the announcement of the law mandating the mentioning of list prices, which applies to prescription pharmaceuticals involved by Medicare or Medicaid that cost at least $35 for a month’s supply or the usual process of treatment, Mr. Azar did not understate its importance.